ATTR-CM

Emboli are a common complication of amyloid transthyretin cardiomyopathy (ATTR-CM). This study found that the CHA2DS2-VASc score is not useful in predicting embolic events in ATTR-CM patients with or without AF, and that VKAs and DOACs are equally effective in preventing embolism, in this scenario. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative illness with a...

A recent study examined the confounding effect of mortality on the frequency of CV-related hospitalization in patients in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). The impact of tafamidis on CV-related hospitalization was underestimated in the ATTR-ACT, according to researchers. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by the buildup of amyloid...

Clinical awareness and early detection of ATTR-CM may be lacking. One study assessed the degree to which there is a lack of awareness among clinicians and offered suggestions on how to resolve it. ATTR-CM, or transthyretin amyloid cardiomyopathy, is a disease that is often misdiagnosed. ATTR-CM presents as a restrictive cardiomyopathy and is associated with...

Data suggests that patients with transthyretin cardiomyopathy (ATTR-CM) have short survival times and high medical costs. One study assessed the burden of disease and medical costs for patients with ATTR-CM. Transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed disease with a poor prognosis that generally affects patients over the age of 60. Because of differences in genotype...

Patients with the A97S genotype of ATTR-CM may exhibit functional and structural improvements after tafamidis treatment. A recent case study showcased these potential benefits. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure. Mutations in the TTR gene are thought to destabilize and change the shape of the protein. Although under-represented in major...

In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin amyloid cardiomyopathy (ATTR-CM). Treatment with dapagliflozin was found to be well-tolerated in patients with ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart disease that can be fatal. In recent years, more and more people have been diagnosed and subsequently hospitalized...

Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation and flutter. Routine ambulatory monitoring in patients with ATTR-CM could help drive the use of anticoagulation to prevent strokes. Heart complications, such as heart failure, are common in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). Atrial fibrillation and flutter (AF/AFL), in...

The awareness and diagnosis of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is challenging, despite ATTRwt being more common than previously thought. Screening is necessary for early detection and diagnosis of ATTRwt CM, as well as for timely treatment of the disease. The clinical characteristics of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) can vary among affected...

Heart failure, among other cardiovascular problems, is a typical manifestation of transthyretin amyloidosis cardiomyopathy (ATTR-CM). The prevalence of ATTR-CM as a phenotype of heart failure is often underestimated. Heart failure with preserved ejection fraction (HFpEF) affects more than half of patients with heart failure. The phenotypes of heart failure can vary, and treatment modalities are...